
News|Articles|July 2, 2018
- Pharmaceutical Technology\'s In the Lab eNewsletter-07-03-2018
- Volume 13
- Issue 7
Sciex’s New Mass Spec Technologies Enhance Lab Analytics
Author(s)Pharmaceutical Technology Editors
Sciex’s latest additions to its biopharma portfolio helps to optimize workflow for better analytics in the lab.
Sciex’s latest additions to its biopharma portfolio help to optimize workflow for better analytics in the lab.
According to the company, these products have been optimized for maximal sensitivity, accuracy, and efficiency for scientists using challenging workflows in critical fields without sacrificing robustness or ease of use.
Recent additions to the Sciex biopharma portfolio include:
- OptiFlow Quant Solution, which delivers highly sensitive micro-flow quantitation for peptides. This solution includes the OptiFlow Turbo V Source with M5 MicroLC to deliver micro-flow sensitivity at analytical flow usability, with flexible and user-friendly sample handling.
- Multiple Attribute Methodology (MAM) Workflow for simplified, in-depth liquid chromatography-mass spectrometry characterization and development of biologics. The MAM Workflow provides complete analysis of the product quality profile while minimizing the burden of product-quality attribute monitoring and product purity testing and uses the company’s BioPharmaView 3.0 software.
- the SCIEX OS 1.4 software brings the full package for quantitative and qualitative analysis to the majority of SCIEX instruments. The new operating system also offers complete 21 CFR Part 11 compliance for labs in regulated fields.
- the MPX 2.0 software, which was recently developed for multiplexing liquid chromatography separations within a single mass spectrometry system, saves valuable laboratory time while improving flexibility, according to the company.
The company showcased these innovations at ASMS 2018 on June 3–7, 2018 in San Diego, CA.
Source:
Articles in this issue
over 8 years ago
Dissolution Testing: Keeping It Simpleover 8 years ago
Improvements Needed for Adventitious Agent Testingover 8 years ago
Alcami Expands Laboratory Services Programover 8 years ago
Shimadzu’s New Q-TOF System Enhances Mass Spectrometryover 8 years ago
Waters’ New UPLC Platform Meets Evolving Chromatography Needsover 8 years ago
Juniper Pharma Services Expands Laboratory Facilitiesover 8 years ago
Micromeritics Acquires Freeman TechnologyRelated to this article

Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.

OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.

Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.

FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.

Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.

Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.

Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Germany’s Medical Biotechnology Sector is Flourishing
3
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
4
Sustainability in Healthcare Packaging: The Journey From Yesterday to Tomorrow
5


